Skip to Content

Ifosfamide Dosage

Medically reviewed by Drugs.com. Last updated on Mar 28, 2019.

Applies to the following strengths: 1 g; 3 g; 50 mg/mL

Usual Adult Dose for Testicular Cancer

1.2 g/m2 IV over at least 30 minutes daily for 5 consecutive days; repeat every 3 weeks or after recovery from hematologic toxicity

Comments:
-To prevent bladder toxicity, this drug should be given with extensive hydration (at least 2 liters of oral or IV fluid daily).
-Mesna should be used to reduce hemorrhagic cystitis.

Use: For use in combination with other antineoplastic agents for third-line chemotherapy of germ cell testicular cancer

Renal Dose Adjustments

Dose adjustment may be required; however, no specific guidelines have been suggested. Caution recommended.

Liver Dose Adjustments

Use with caution.

Precautions

US BOXED WARNINGS:
MYELOSUPPRESSION:
-Myelosuppression can be severe and lead to fatal infections.
Recommendation:
-Monitor blood counts prior to and at intervals after each treatment cycle.
NEUROTOXICITY:
-CNS toxicities can be severe and result in encephalopathy and death.
Recommendation:
-Monitor for CNS toxicity and discontinue treatment for encephalopathy.
UROTOXICITY:
-Nephrotoxicity can be severe and result in renal failure.
Recommendation:
-Hemorrhagic cystitis can be severe and can be reduced by the prophylactic use of mesna.

CONTRAINDICATIONS:
-Hypersensitivity to the active component or any of the ingredients
-Urinary outflow obstruction

Safety and efficacy have not been established in patients younger than 18 years.

Consult WARNINGS section for additional precautions.

Dialysis

This drug is dialyzable; however, no dose adjustment guidelines have been reported.

Other Comments

Administration advice:
-This drug should be administered as a slow IV infusion lasting a minimum of 30 minutes.

Storage requirements:
-Store unopened vials in a refrigerator 2C to 8C (36F to 46F).
-Diluted solutions of this drug should be refrigerated and used within 24 hours.

Reconstitution/preparation techniques:
-The manufacturer product information should be consulted. Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit.

IV compatibility:
-This drug is compatible with 5% dextrose injection, 0.9% sodium chloride injection, Lactated Ringer's injection, and sterile water for injection.

General:
-Handling and preparation of this drug should be in accordance with current guidelines on safe handling of cytotoxic agents.
-Skin reactions associated with accidental exposure to this drug may occur. Wear impervious gloves when handling vials and solutions. If this drug contacts the skin or mucosa, immediately wash the skin thoroughly with soap and water or rinse the mucosa with copious amounts of water.

Monitoring:
-Serum and urine chemistries

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Hide